Beyond Air Inc represents a commitment to improving patient outcomes through innovative medical technologies. The company's corporate philosophy revolves around developing and commercializing potentially groundbreaking treatments for life-threatening respiratory conditions. With a focus on advanced inhalation therapies, Beyond Air aims to provide safe and effective solutions that enhance the quality of life for patients. By harnessing the power of its proprietary technology and a dedicated team of experts, Beyond Air Inc strives to establish itself as a leading player in the healthcare industry, delivering value to both patients and investors.

Beyond Air Inc is primarily present in the United States.

Beyond Air Inc has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for its lung infection therapy, demonstrating positive results. Beyond Air Inc also received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their nitric oxide generator and delivery system. In addition, the company expanded their market reach through strategic collaborations and partnerships with various organizations. Furthermore, Beyond Air Inc has made progress in developing innovative and effective respiratory treatments to address unmet medical needs. These milestones highlight the company's commitment to advancing healthcare solutions and driving growth in the industry.

Beyond Air Inc, founded in 2011, is a leading medical device company specializing in the development of Nitric Oxide (NO) delivery systems for various respiratory conditions. The company focuses on developing innovative technologies that harness the therapeutic potential of NO, known for its antimicrobial and vasodilatory properties. Beyond Air Inc's flagship product, LungFit™️, is a compact and user-friendly system designed to deliver NO gas directly to patients' lungs, potentially benefiting conditions like bronchiolitis, cystic fibrosis, chronic obstructive pulmonary disease (COPD), and more. With a commitment to improving respiratory health, Beyond Air Inc continues to pioneer the use of NO in clinical settings, promoting better patient outcomes and enhancing pulmonary care.

Beyond Air Inc's main competitors in the market include established companies such as Aimmune Therapeutics, Breathe Technologies, and ResMed. These companies operate in the healthcare and medical device industry, offering products and services that may overlap with Beyond Air Inc's innovative solutions. However, Beyond Air Inc distinguishes itself through its unique technologies and product offerings, positioning itself as a strong contender in the market.

Beyond Air Inc is primarily active in the medical devices industry.

The business model of Beyond Air Inc focuses on the development and commercialization of innovative medical devices for the treatment of respiratory conditions. They specialize in the production of Nitric Oxide (NO) technology solutions, such as the LungFit™ system, which delivers precise amounts of NO gas to patients. Beyond Air Inc aims to provide convenient and effective treatment options for various pulmonary diseases, including bronchiolitis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). By leveraging their expertise in NO therapy, Beyond Air Inc strives to improve patients’ quality of life and advance respiratory healthcare.

Pašreizējais KGV Beyond Air nevar tikt aprēķināts.

KUV šobrīd Beyond Air nevar aprēķināt.

AlleAktien kvalitātes vērtējums Beyond Air ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu Beyond Air.

Pašlaik peļņa Beyond Air nevar tikt aprēķināta.

Beyond Air Inc. is a leading company in the field of medical technology, focusing on the development and marketing of groundbreaking medical products to improve patient healing. The company is based in New York City and operates subsidiaries in Europe, Israel, and Australia. The company is divided into several business segments, including Respiratory Care, Nitric Oxide Delivery, Medical Device Development, and Pharma Solutions. Each of these business segments is focused on developing and marketing innovative solutions for various health challenges. Within the Respiratory Care division, Beyond Air offers a wide range of therapy and diagnostic products for the treatment of respiratory diseases such as asthma, COPD, and pneumonia. This includes products like the LungFit Systems, which help users improve their breathing and increase lung function. Beyond Air is also a leading provider of Nitric Oxide Delivery solutions, which allow hospitals to deliver nitric oxide in high quality and precise doses. Nitric oxide is an important gas used in the treatment of patients with respiratory diseases. The company has developed a range of devices that can be used to deliver this gas, including the innovative LungFit™️ system. In the field of medical device development, the company offers a wide range of unique solutions aimed at improving patient healing. This includes products like the Beyond Air Oasis Inhaler, which enables quick and easy medication absorption and is ideal for the treatment of respiratory diseases. In addition to these products, Beyond Air also offers a wide range of Pharma Solutions. The company has its own team of experts in drug development and focuses on developing innovative ways to treat diseases such as cancer. This includes products like the innovative Beyond Air Nitric Oxide Cancer Treatment (NOCT) system, which is used to support chemotherapy. Overall, Beyond Air Inc. is committed to developing and marketing innovative solutions for a wide range of health problems. The company benefits from a strong culture of innovation and a clear focus on patient needs. With its broad product range and global presence, Beyond Air is well positioned to continue growing and playing a leading role in the medical technology industry.

Beyond Air izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Beyond Air vai uzņēmums nedod dividendes.

Beyond Air ISIN ir US08862L1035.

Beyond Air WKN ir A2PNGL.

Beyond Air simbols ir XAIR.

Pēdējo 12 mēnešu laikā Beyond Air maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Beyond Air plāno maksāt dividendes 0 USD apmērā.

Beyond Air pašreizējā dividendu rentabilitāte ir .

Beyond Air maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Beyond Air pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Beyond Air tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Beyond Air apmērā 0 USD, kas tika izmaksāta 1.10.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.10.2024..

Pēdējās dividendes izmaksa notika 1.10.2024..

Gadā 2023, Beyond Air izmaksāja 0 USD dividendes.

Beyond Air dividendes tiek izmaksātas USD.